Piper Jaffray Companies set a $18.00 price target on Horizon Pharma PLC (NASDAQ:HZNP) in a report issued on Sunday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

HZNP has been the subject of several other reports. BidaskClub downgraded Horizon Pharma PLC from a buy rating to a hold rating in a research note on Monday, July 31st. ValuEngine downgraded Horizon Pharma PLC from a buy rating to a hold rating in a research note on Friday, September 1st. Cantor Fitzgerald reiterated a buy rating and set a $17.00 target price on shares of Horizon Pharma PLC in a research note on Tuesday, September 26th. Cowen and Company reiterated a buy rating on shares of Horizon Pharma PLC in a research note on Thursday, September 28th. Finally, BMO Capital Markets reiterated an outperform rating and set a $18.00 target price (up from $17.00) on shares of Horizon Pharma PLC in a research note on Thursday, August 10th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $18.00.

Horizon Pharma PLC (HZNP) opened at 13.83 on Friday. The stock’s 50 day moving average price is $13.13 and its 200-day moving average price is $12.68. The firm’s market capitalization is $2.26 billion. Horizon Pharma PLC has a one year low of $9.45 and a one year high of $21.98.

Horizon Pharma PLC (NASDAQ:HZNP) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.12 by $0.29. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. The company had revenue of $289.51 million during the quarter, compared to the consensus estimate of $237.01 million. During the same period in the previous year, the company posted $0.56 EPS. The firm’s revenue for the quarter was up 12.5% compared to the same quarter last year. On average, equities research analysts expect that Horizon Pharma PLC will post $1.07 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/piper-jaffray-companies-reiterates-18-00-price-target-for-horizon-pharma-plc-hznp/1640162.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Prudential Financial Inc. raised its holdings in Horizon Pharma PLC by 2.6% in the 1st quarter. Prudential Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $247,000 after acquiring an additional 420 shares in the last quarter. Sheaff Brock Investment Advisors LLC raised its holdings in Horizon Pharma PLC by 5.0% in the 2nd quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 500 shares in the last quarter. Amalgamated Bank raised its holdings in Horizon Pharma PLC by 4.8% in the 2nd quarter. Amalgamated Bank now owns 20,711 shares of the biopharmaceutical company’s stock valued at $246,000 after acquiring an additional 943 shares in the last quarter. Bank of Montreal Can raised its holdings in Horizon Pharma PLC by 16.3% in the 2nd quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 1,378 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in Horizon Pharma PLC by 1.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 125,933 shares of the biopharmaceutical company’s stock valued at $1,495,000 after acquiring an additional 1,379 shares in the last quarter. 82.32% of the stock is owned by hedge funds and other institutional investors.

About Horizon Pharma PLC

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Analyst Recommendations for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.